Bolt Biotherapeutics Reports Q2 2026 Financial Results with $7.7M Net Loss

Bolt Biotherapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $7.7 million, a slight improvement from the $8.6 million loss recorded in the same period of 2025. For the first half of 2026, the company reported a net loss of $15.0 million, compared to $19.6 million for the first half of 2025. The company’s collaboration revenue significantly decreased to $5,000 for the second quarter and $31,000 for the first half of 2026, down from $1.8 million and $3.0 million, respectively, in the prior year. This decline is attributed to reduced activities with collaboration partners, reflecting the ongoing challenges in the biopharmaceutical sector.

Operating expenses for the second quarter of 2026 totaled $8.4 million, down from $11.0 million in the same quarter of 2025. The decrease was primarily driven by a reduction in research and development expenses, which fell to $5.1 million from $7.5 million year-over-year, largely due to a workforce reduction implemented in October 2025. General and administrative expenses also decreased to $2.4 million from $3.5 million, reflecting similar cost-cutting measures. The company recognized impairment charges of $0.8 million in the second quarter of 2026, related to a triggering event from a sublease termination.

As of June 30, 2026, Bolt Biotherapeutics reported total assets of $40.3 million, a decrease from $56.7 million at the end of 2025. Current assets were $20.6 million, down from $30.3 million, primarily due to a reduction in short-term investments. The company’s cash and cash equivalents increased to $12.9 million from $11.7 million, while total liabilities decreased to $27.7 million from $30.2 million. The accumulated deficit stood at $475.7 million, reflecting the ongoing financial challenges faced by the company.

In terms of strategic developments, Bolt Biotherapeutics continues to focus on its clinical-stage pipeline, particularly the BDC-4182 program targeting claudin 18.2 for cancer treatment. The company is actively conducting a Phase 1/2 clinical trial for this candidate. However, the company has indicated that it will need to raise additional capital to support its ongoing research and development activities, as its current cash reserves may only sustain operations into the first quarter of 2027. The company has expressed substantial doubt about its ability to continue as a going concern within the next year, emphasizing the need for strategic partnerships or financing to ensure its operational viability.

Looking ahead, Bolt Biotherapeutics anticipates continued fluctuations in collaboration revenue and operating expenses as it navigates the complexities of clinical development and market conditions. The company remains committed to advancing its product candidates while managing its financial resources prudently. The outlook for the remainder of 2026 will depend on the success of its clinical trials, the ability to secure additional funding, and the overall market environment for biopharmaceuticals.